Stock Alert for Vermillion Inc. (VRML)

Vermillion Inc. (VRML) and its subsidiaries engage in the discovery, development, and commercialization of diagnostics tests that help physicians to diagnose and treat patients. The Company develops novel diagnostic tests in the fields of oncology, hematology, cardiology, and women’s health with the initial focus on ovarian cancer. Its lead product includes the OVA1 ovarian tumor triage test (the OVA1 Test), which addresses pre-surgical identification of women who are at high risk of having a malignant ovarian tumor. The Company has collaborations with various academic and research institutions, including The Johns Hopkins University School of Medicine; The University of Texas M.D. Anderson Cancer Center; University College London; The University of Texas Medical Branch; The Katholieke Universiteit Leuven; Clinic of Gynecology and Clinic of Oncology, Rigshospitalet; Copenhagen University Hospital; The Ohio State University Research Foundation; Stanford University; and the University of Kentucky. It also has strategic alliance agreement with Quest Diagnostics Inc. to develop and commercialize up to three diagnostic tests. VRML serves clinical reference laboratories, hospital laboratories and physician offices.

Share Statistics (27-Mar-12)   FY












Symbol VRML Revenue, $Mn 0.00 1.18 0.30 0.32 6.67%
Current price $1.77 Gross marg. 0.00% 92.37% 90.00% 90.63% 0.70%
52wk Range: $0.97-$7.60 Oper. margin -1987.40% -1427.81%
Avg Vol (3m): 485019 Net margin -1612.71% -1909.33% -1453.13% -23.89%
Market Cap. 26.30M              
Shares Outstanding 14.86M EPS, $ -3.03 -0.99 -67.33% -0.39 -0.31 -20.52%

Source:, SEC Filings.

Investment Highlights

VRML shares headed higher on Tuesday after the Company announced its fourth quarter and full year 2011 results, which showed strong increases in total revenues and lower net losses.

Shares in the Austin, TX-based company added 12.03% to close at $1.77, with over 2.52 million shares traded.  The stock has so far reached a 52-week high of $7.60, its 52-week low being $0.97.

Shares have risen 11.3% in the last five trading days and 37.2% in the last month.  Year-to-date, the stock is down 62.1%.

Total revenues in the December quarter rose 152% to $868K from $345K in the comparable quarter of the previous year.  The latest quarterly result included included $755K from product sales of OVA1, the Company’s flagship diagnostic designed to help differentiate benign from malignant ovarian masses, and $113K of license revenue related to the VRML’s achievement of certain milestones under its amended strategic alliance agreement with Quest Diagnostics.

For the full year, total revenues were $1.9 million, an increase of 64% from fiscal 2010. Full-year 2011 revenues included $1.5 million from product sales of OVA1 and $454K of license revenue. Product sales of OVA1 in 2011 include $761K from 15,225 OVA1 tests performed at the fixed $50 per test, $549K for the 33% royalty reported by Quest Diagnostics for 2011, and $159K for the 33% royalties reported by Quest Diagnostics for 2010. The 2010 royalty was reported to the company and recorded in the first quarter of 2011.

VRML realized a net loss $3.1 million, or $(0.21) per share, for the last three months of 2011, as compared to $4.0 million, or $(0.38) per share, in the same year-ago quarter. Net loss for 2010 included $8.6 million in reorganization items and $4.4 million in gains resulting from the exercise and fair value revaluation of common stock warrants. Net loss for 2011 came in at $17.8 million, or $(1.25) per share, as compared to $19.0 million, or $(1.83) per share in 2010.

As of December 31, 2011, VRML’s cash and cash equivalents totaled $22.5 million. The Company used $5.0 million in cash from operations during the fourth quarter, including $435,000 for the Correlogic asset acquisition.

Gail S. Page, president and CEO of VRML, made the following statements: “2011 showed substantial expansion in OVA1 tests usage leading to another year of revenue growth for Vermillion.  In fact, more than 3,700 or 11% of the nation’s gynecologists — the professionals who help define the standard of care for women with ovarian cancer — ordered OVA1 in 2011. The specialist sub-group of gynecologic oncologists supporting OVA1 also grew by 24 in the fourth quarter, bringing the total to more than 275. Given the relatively short period of time this test has been on the market, this represents strong traction and increasing brand awareness within the gynecologist community. This strong progress was matched by increased OVA1 payer coverage in 2011 and the addition of the Department of Defense payer coverage in January 2012.”

VRML earlier this month announced the American Medical Association (AMA) Current Procedural Terminology (CPT) Panel has voted to approve an application for a Category 1 CPT code for its OVA1 test.  According to CEO Page, this approval was supported by several peer-reviewed publications and positive coverage decisions, including Medicare.

“The new CPT code is a critical step in advancing the commercialization of OVA1, as we believe it will help streamline claims processing and accelerate further coverage and adoption by private payers.”


Financial Strength (27-Mar-2012)




Quick Ratio (MRQ) 1.63 1.42
Current Ratio (MRQ) 4.35 2.14 1.76
LT Debt to Equity (MRQ) 53.13 23.53 27.21
Total Debt to Equity (MRQ) 53.13 58.03 36.23
Interest Coverage (TTM) 1.95 2.39

Source:, SEC Filings.

Technical Analysis


VRML is within its Bollinger Bands. This is a normal condition suggesting that it is neither overbought nor oversold relative to the recent levels.

VRML’s MACD is indicating a weak bearish signal. Although the indicator is above the critical level of 0, which implies that the underlying moving averages are bullish, the MACD has crossed below its 9minute moving average or signal line. This suggests that positive momentum has begun to slow.

Comparative Analysis

Company Name Ticker Price per Mrkt. Cap. P/E P/S
Mar27-2012 symbol Share, $ $ Mn 2012 2013 2012 2013
OraSure Technologies Inc. OSUR 11.43 550.64M n/a 127 5.50 4.48
Abbott Laboratories ABT 61.33 96.43B 12.24 11.46 2.42 2.34
Diagnostic Substances  Median       30.38 n/a 4.95 n/a
Vermillion Inc VRML 1.77 26.30M n/a n/a 15.03 10.56

Source: Thomson Financial

DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the “SEC”) or with any state securities regulatory authority.  We are neither licensed nor qualified to provide investment advice.

The information contained in our report should be viewed as commercial advertisement and is not intended to be investment advice.  The report is not provided to any particular individual with a view toward their individual circumstances. The information contained in our report is not an offer to buy or sell securities.  We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.

Our newsletter and website have been prepared for informational purposes only and are not intended to be used as a complete source of information on any particular company.  An individual should never invest in the securities of any of the companies profiled based solely on information contained in our report.  Individuals should assume that all information contained in the report about profiled companies is not trustworthy unless verified by their own independent research.

Any individual who chooses to invest in any securities should do so with caution.  Investing in securities is speculative and carries a high degree of risk; you may lose some or all of the money that is invested.  Always research your own investments and consult with a registered investment advisor or licensed stock broker before investing.

Information contained in our report will contain “forward looking statements” as defined under Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934.  Subscribers are cautioned not to place undue reliance upon these forward looking statements.  These forward looking statements are subject to a number of known and unknown risks and uncertainties outside of our control that could cause actual operations or results to differ materially from those anticipated.  Factors that could affect performance include, but are not limited to, those factors that are discussed in each profiled company’s most recent reports or registration statements filed with the SEC.  You should consider these factors in evaluating the forward looking statements included in the report and not place undue reliance upon such statements.

We are committed to providing factual information on the companies that are profiled.  However, we do not provide any assurance as to the accuracy or completeness of the information provided, including information regarding a profiled company’s plans or ability to effect any planned or proposed actions.  We have no first-hand knowledge of any profiled company’s operations and therefore cannot comment on their capabilities, intent, resources, nor experience and we make no attempt to do so.  Statistical information, dollar amounts, and market size data was provided by the subject company and related sources which we believe to be reliable.

To the fullest extent of the law, we will not be liable to any person or entity for the quality, accuracy, completeness, reliability, or timeliness of the information provided in the report, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of information we provide to any person or entity (including, but not limited to, lost profits, loss of opportunities, trading losses, and damages that may result from any inaccuracy or incompleteness of this information).

We encourage you to invest carefully and read investment information available at the websites of the SEC at and FINRA at

Leave a Reply

Your email address will not be published. Required fields are marked *